Baseline characteristics of TZD exposure groups among controls (n=6699)				
	Exclusive ever use of pioglitazone (n=191)	Exclusive ever use of rosiglitazone (n=596)	Ever use of both TZDs (n=56)	Never use of any TZD (n=5856)
Excessive alcohol use, n (%)	14 (7.3)	35 (5.9)	6 (10.7)	375 (6.2)
Body mass index, n (%)				
< 30 kg/m^2	104 (54.5)	322 (54.0)	30 (53.6)	3715 (63.4)
≥ 30 kg/m^2	87 (45.6)	269 (45.1)	26 (46.4)	2034 (34.7)
Unknown	0 (0.0)	5 (0.8)	0 (0.0)	107 (1.8)
Smoking status, n (%)				
Never	73 (38.2)	251 (42.1)	30 (53.6)	2389 (40.8)
Ever	107 (56.0)	305 (51.2)	23 (41.1)	2926 (50.0)
Unknown	11 (5.8)	40 (6.7)	3 (5.4)	541 (9.2)
HbA$_{1c}$, n (%)				
≤ 7.4 %	91 (47.6)	310 (52.0)	27 (48.2)	2956 (50.5)
>7.4 %	85 (44.5)	250 (42.0)	27 (48.2)	1680 (28.7)
Unknown	15 (7.9)	36 (6.0)	2 (3.6)	1220 (20.8)
Previous bladder conditions, n (%)	12 (6.3)	33 (5.5)	7 (12.5)	283 (4.8)
Previous cancer, n (%)[a]	14 (7.3)	35 (5.9)	3 (5.4)	429 (7.3)
Charlson comorbidity score, mean (SD)	0.83 (1.04)	0.80 (1.04)	0.98 (1.04)	0.97 (1.18)
Anti-diabetic drugs[b], n (%)				
Metformin	114 (60.0)	350 (58.7)	38 (67.9)	3121 (53.3)
Sulfonylurea	56 (29.3)	220 (36.9)	17 (30.4)	2751 (47.0)
TZD	23 (12.0)	29 (4.9)	2 (3.6)	0 (0.0)
Other agents	1 (0.5)	12 (2.0)	0 (0.0)	54 (0.9)

Abbreviations: RR, rate ratio; CI, confidence interval; SD, standard deviation; TZD, thiazolidinedione.

[a] Cancers other than non-melanoma skin cancer.

[b] Non-mutually exclusive groups since patients could have received more than one oral hypoglycaemic agent at cohort entry.